Deadline: 11-Sep-2025
Pfizer Inc. and the American Gastroenterological Association (AGA) have launched a grant opportunity for innovative research aimed at improving the diagnosis and treatment of inflammatory bowel disease (IBD). The initiative invites proposals through a public Request for Proposal (RFP), which outlines the areas of interest and timelines. AGA will form an Expert Review Panel to select grantees, support collaboration, and promote knowledge sharing.
The call focuses on two key areas. First, it seeks studies using real-world data to examine IBD practice patterns, especially related to S1P receptor modulators. This includes their role in managing extra-intestinal manifestations, their use in combination or sequence with other therapies, and evaluating their safety and efficacy in other gastrointestinal conditions such as Crohn’s disease, eosinophilic esophagitis, and colitis variants.
The second focus is on novel diagnostic and monitoring methods. Proposals may explore the use of artificial intelligence and machine learning to identify patients likely to respond to treatments. Other interests include evaluating intestinal ultrasound (IUS) for disease monitoring, applying AI in endoscopic assessments, implementing treat-to-target strategies, and utilizing clinical, biomarker, or omics data to predict treatment responses in IBD.
Each selected project may request up to $60,000 in funding, and projects must be completed within one year. Only U.S.-based institutions are eligible, and the Principal Investigator (PI) must be a member of the AGA. Applicants must be affiliated with a legal entity such as a hospital, university, or non-profit organization.
Eligible PIs must hold a doctoral-level medical, pharmacy, nursing, or related degree, and be employed or contracted by the requesting institution. Grants cannot be awarded to individuals or informal physician groups. Applicants should confirm their institution is able to receive funds directly from Pfizer before applying, as failure to meet this requirement may lead to withdrawal of the grant.
For more information, visit Pfizer.
